Rebecca Frey, Chief Executive Officer and Director of Yarrow Bioscience, Inc., filed a Form 4 on October 30, 2026, disclosing the acquisition of a stock option to purchase 465,857 shares of the company's common stock, with a transaction date of October 29, 2026.

Key Highlights

  • Reporting person: Rebecca Frey, Director and Chief Executive Officer of Yarrow Bioscience, Inc. (NASDAQ:YARW)
  • Security acquired: Stock Option (Right to Buy) covering 465,857 shares of common stock, acquired on October 29, 2026
  • Exercise price: $20 per share, with an expiration date of October 29, 2036
  • Option price paid: $0 at acquisition
  • Vesting schedule: One quarter vests on July 28, 2027; the remaining three quarters vest in equal monthly installments over the following three years, subject to continued service
  • Post-transaction holdings: 465,857 derivative securities beneficially owned directly following the reported transaction

Yarrow Bioscience CEO Frey's October 2026 Option Award Details

According to the filing, Rebecca Frey, who serves as both Chief Executive Officer and Director of Yarrow Bioscience, Inc. (NASDAQ:YARW), acquired a stock option granting her the right to purchase 465,857 shares of the issuer's common stock. The transaction was recorded with a date of October 29, 2026, and the form was filed on October 30, 2026. The option was classified under transaction code "A" (acquisition) and is held directly by the reporting person.

The filing discloses that the exercise price of the stock option is $20 per share, with an expiration date of October 29, 2036, giving the option a ten-year term. The price of the derivative security at acquisition was reported as $0. The filing states that the option "represents a right to purchase 465,857 shares of the Issuer's common stock, one quarter of which will vest on July 28, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date."

The form was filed by one reporting person and was signed by Tyler Zeronda as attorney-in-fact for Rebecca Frey. No transactions were reported in Table I covering non-derivative securities. Following the reported transaction, the filing indicates Frey beneficially owns 465,857 derivative securities directly.

What Was Disclosed

Yarrow Bioscience CEO and Director Rebecca Frey disclosed the acquisition of a stock option to purchase 465,857 shares of common stock at $20 per share, expiring October 29, 2036, with a four-year vesting schedule beginning July 28, 2027, subject to continued service.